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Objectives: To evaluate the cost-effectiveness of canagliflozin, an active inhibi-
tor of sodium glucose co-transporter – 2 (SGLT2) in dual therapy as add-on to 
metformin compared to sitagliptin and glimepiride. Canagliflozin in clinical trial 
results showed effective glucose reduction, along with other benefits in diabetes 
treatment including weight loss and SBP reduction. Cost effectiveness analyses 
were conducted in the Polish setting from a public perspective in accordance with 
guidelines of Polish HTA Agency (PolAHTA). MethOds: The IMS CORE Diabetes 
Model was used to evaluate the cost-effectiveness of canagliflozin versus the 
aforementioned comparators using Polish-specific data, where available. Direct 
costs were reported in Polish zloty and an annual discount rate of 5% and 3.5% 
were applied on costs and effects respectively. Results: In dual therapy as add-on 
to metformin, canagliflozin 100 mg dominates sitagliptin with average cost savings 
of 2 811 zł and an average QALY gain of 0.06, canagliflozin 300 mg is cost effective 
option in comparison to sitagliptin with an incremental cost effectiveness ratio 
(ICER) of 45 008 zł per QALY and QALY gain of 0.09. As add-on to metformin cana-
gliflozin is a cost effectiveness option in comparison with glimepiride with ICER 
of 28 454 zł and 73 102 zł, QALY gain 0,112 QALY and 0,140 QALY for canagliflozin 
100 mg and 300 mg respectively. All results are below defined in Polish reimburse-
ment act cost-effectiveness threshold. cOnclusiOns: These results suggest that 
adding Canagliflozin to metformin versus sitagliptin or glimepiride in patients 
inadequately controlled with metformin would be a more efficient use of health 
care resources in the Polish setting.
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Objectives: To evaluate the cost-effectiveness of interventions aimed at decreas-
ing the number of amputations among patients with diabetic foot ulcers (DFU) in 
Russia. MethOds: We have modeled the changes in the annual outcomes (minor 
and major amputations) and costs (services provided in outpatient clinics and hos-
pitals, medications, orthopedic shoes and prosthetic devices and services provided 
in case of amputation) from the perspective of public health and social care. Two 
interventions were assessed: preventive services for patients with the very high risk 
of DFU (additional outpatient visits for foot care and orthopedic shoes) and provi-
sion of care for DFU patients at hospital by multidisciplinary foot care team (MDT). 
The current number of amputations and costs among DFU patients in Russia was 
assessed on the basis of published Russian data and experts’ survey. The expected 
effectiveness of interventions was derived from the international publications. Costs 
were estimated on the basis on reimbursement rates in public medical insurance 
and social care. Results: The implementation of hospital care by MDT for cohort 
of 1000 DFU patients at the current rate of hospitalizations will require additional 
annual spending of € 532,520, and the expected annual number of major amputa-
tions will decrease by 41. The ICER for this intervention is € 12,988 per prevented 
amputation, which is almost 2 times higher than the costs associated with major 
amputation at the current moment. For the preventive services, if all patients are 
compliant, additional costs per prevented amputation are slightly lower - € 10,216, 
but also well above the costs of major amputation. cOnclusiOns: Both interven-
tions require considerable additional budget spending. Preventive measures, if all 
the patients follow the recommendations, are more cost effective than introduction 
of hospital MDT.
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Objectives: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor 
used in treatment of patients with type 2 diabetes mellitus (T2DM). The objective 
is to estimate the cost-effectiveness of canagliflozin (100mg once daily and 300mg 
once daily) compared with liraglutide in combination with metformin and sulfony-
lurea (SU) for the treatment of T2DM inadequately controlled with metformin and 
SU in France. MethOds: The IMS CORE Diabetes Model was used to project clinical 
and economic outcomes for patients with T2DM treated with canagliflozin or lira-
glutide, each in combination with metformin and SU. Since direct trial data were not 
available, the relative treatment effects on HbA1c, SBP and BMI for liraglutide 1.8mg 
in combination with metformin and SU were derived from a network meta-analysis 
(NMA) of treatment effects at 26 weeks. This study is limited by the absence of direct 
or indirect data on the effect of liraglutide 1.2mg in combination with metformin 
and SU, therefore the relative treatment effects on HbA1cand BMI at 26 weeks for 
liraglutide 1.2mg were estimated using the dose-response relationship from a NMA 
based on treatments in combination with metformin only. French market share 
data were used to weight the results of liraglutide 1.8mg and 1.2mg. Results: 
Canagliflozin 100mg showed cost savings when compared to treatment with lira-
glutide (1,388 € ); incremental QALYs were estimated as -0,035. Canagliflozin 300 
mg was dominant, with cost savings of 1,411 € and relatively small incremental 
QALY gain of 0.003. cOnclusiOns: The analyses found that treatment of T2DM 
with canagliflozin 100mg or 300mg instead of liraglutide as add on to metformin 
Markov/Monte Carlo simulation techniques to describe the long-term incidence 
and progression of diabetes-related complications. It was used to simulate disease 
progression in a cohort of patients with baseline characteristics (mean age 18.6 
years, duration of diabetes 12 years, mean HbA1c 7.5%) and clinical outcomes 
(severe hypoglycaemic event rates; Quality of Life; HbA1c) taken from a recent 
randomised controlled trial (Ly et al, 2013). Local treatment and complication cost 
data was used. The main scenario considered in this cost-effectiveness analysis 
was the comparison of sensor-augmented insulin pump (SAP) with low glucose 
suspend (LGS) versus insulin pump alone (CSII). The target population was type I 
hypo-prone diabetes patients with the analysis based on a deterministic micro-
simulation of 1,000 patients, using a 5 year time horizon. Direct costs were calcu-
lated from a third-party payer perspective. Discount rates of 3% per annum were 
applied to both costs and clinical outcomes. Results: The Incremental-Cost-
Effectiveness-Ratio (ICER) for SAP+LGS (vs CSII) was € 17,893 per Quality-Adjusted-
Life-Year gained over a 5 year time horizon. Results were similar across a 1 to 10 
year time horizon. Other extensive sensitivity analyses showed the robustness 
of the results. cOnclusiOns: Using a payer’s perspective, our analysis showed 
that SAP (w LGS) is cost-effective over a short term (5 year) time horizon in hypo-
prone Type 1 Diabetes patients in Slovakia (using a WTP threshold of 1x [€ 18,000] 
or 3x [€ 54,000] Slovakia GDP).
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Objectives: A RCT assessed the effectiveness and costs of a home based video 
teleconsultation (HVT) setup to lower HbA1c in patients with type-2 diabetes 
against usual out-patient treatment on the hospital. The HVT equipment was 
delivered to the patients by the hospital. This analysis shows the potential incre-
mental cost-effectiveness ratio (ICER) of using a HVT setup on six-months health 
care effects and costs. MethOds: The study effectiveness outcome was HbA1c 
level in %. The economic analysis was performed with a spreadsheet decision 
tree model with a Danish hospital payer’s direct cost perspective. Cost data were 
based on study measured time consumption pr. HVT, consultations at out-patient 
clinic, HVT-equipment, -subscription, -support costs, and hospital operating cost. 
Medicine costs weren’t included in the model. Model output included the cost 
of a 1 % point reduction of HbA1c, ICER, with a probabilistic sensitivity analysis 
(PSA). Two scenario analyses (SA) were made to capture costs of patient transport 
to the hospital and a future online platform, were patients can use their own 
computer/tablet to the video teleconsultations. Results: A total of 39 patients 
(mean age 62, HbA1c 8.5%) were randomized to either usual care (UC) or HVT. At 
6 months follow up the HVT group showed greater improvements from baseline 
HbA1c levels (-1.38% vs. -0.92%) and less costly (€ 199.9 vs. € 208.2) against UC. The 
base case ICER showed a potential € –17.58 saving per reduction of 1% HbA1c point. 
A PSA confirmed the ICER trends despite data uncertainties. Both SA showed 
further savings (ICER: € -67.85 and € -69.13). Compliance was 100% for HVT group 
were several planned visits were cancelled in the UC group. cOnclusiOns: The 
present analysis shows the potential benefits of a HVT setup on 6-months health 
care cost and effects against UC. Further savings could include cost associated 
with lost work days.
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Objectives: Sulphonylureas (SU) and insulin are used routinely in the manage-
ment of T2DM but are associated with weight gain and increased risk of hypogly-
caemia. Canagliflozin is a new insulin-independent oral glucose lowering agent 
with added benefits of weight loss, blood pressure reduction and no increased risk 
of hypoglycaemia. This analysis estimated the cost-effectiveness of canagliflozin 
compared to either SU or insulin in patients failing to achieve glycaemic control 
on metformin monotherapy in Ireland. MethOds: The Economic and Health 
Outcomes Model of T2DM (ECHO-T2DM) was used to simulate the lifetime out-
comes and costs associated with canagliflozin (100mg, titrated to 300mg as needed 
to maintain glycaemic control) versus SU and versus insulin glargine. Patient 
characteristics and treatment effects for the SU comparison were sourced from a 
head-to-head randomized clinical trial vs. glimepiride. Hypoglycaemia rates were 
halved to reflect gliclazide MR (the preferred SU in Ireland). Patient characteristics 
for the insulin glargine comparison were obtained from the pooled canagliflo-
zin add-on to metformin RCTs; treatment effects were sourced from a network 
meta-analysis. Costs were localised and inflated to 2013 euros. Utilities were 
sourced from the literature. Costs and outcomes were discounted at 5% annu-
ally. Results: The incremental costs, QALY gains and ICERs associated with 
canagliflozin were € 2,404, 0.215 QALYs and € 11,191 per QALY gained, respectively, 
versus SU and € 2,352, 0.228 QALYs and € 10,305 per QALY gained, respectively, 
versus insulin glargine. Key drivers were decreased hypoglycaemia and lower 
weight-related disutility versus both comparators, as well as better HbA1c durabil-
ity versus SU. In both cases, using an acceptable Irish willingness-to-pay threshold, 
the probability of being cost-effective was in excess of 97%. Sensitivity analyses 
support the robustness of these results. cOnclusiOns: These simulations sug-
gest that canagliflozin is a cost-effective treatment choice versus both gliclazide 
MR and insulin glargine in patients failing to control glycaemia on metformin 
alone.
